Whole-body MRI in oncology: acquisition protocols, current guidelines, and beyond.
Diffusion magnetic resonance imaging
Li-Fraumeni syndrome
Melanoma
Multiple myeloma
Prostate cancer
Whole body imaging
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
14
03
2024
accepted:
04
07
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
Acknowledging the increasing use of whole-body magnetic resonance imaging (WB-MRI) in the oncological setting, we conducted a narrative review focusing on practical aspects of the examination and providing a synthesis of various acquisition protocols described in the literature. Firstly, we addressed the topic of patient preparation, emphasizing methods to enhance examination acceptance. This included strategies for reducing anxiety and patient distress, improving staff-patient interactions, and increasing overall patient comfort. Secondly, we analysed WB-MRI acquisition protocols recommended in existing imaging guidelines, such as MET-RADS-P, MY-RADS, and ONCO-RADS, and provided an overview of acquisition protocols reported in the literature regarding other expanding applications of WB-MRI in oncology, in patients with breast cancer, ovarian cancer, melanoma, colorectal and lung cancer, lymphoma, and cancers of unknown primary. Finally, we suggested possible acquisition parameters for whole-body images across MR systems from three different vendors.
Identifiants
pubmed: 38990426
doi: 10.1007/s11547-024-01851-6
pii: 10.1007/s11547-024-01851-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Italian Society of Medical Radiology.
Références
Eustace S, Tello R, DeCarvalho V, Carey J, Wroblicka JT, Melhem ER, Yucel EK (1997) A comparison of whole-body turbo STIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol 169(6):1655–1661. https://doi.org/10.2214/ajr.169.6.9393186
doi: 10.2214/ajr.169.6.9393186
pubmed: 9393186
Walker R, Kessar P, Blanchard R, Dimasi M, Harper K, DeCarvalho V, Yucel EK, Patriquin L, Eustace S (2000) Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 11(4):343–350. https://doi.org/10.1002/(sici)1522-2586(200004)11:4%3c343:aid-jmri1%3e3.0.co;2-p
doi: 10.1002/(sici)1522-2586(200004)11:4<343:aid-jmri1>3.0.co;2-p
pubmed: 10767062
Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18(9):1937–1952. https://doi.org/10.1007/s00330-008-0968-z
doi: 10.1007/s00330-008-0968-z
pubmed: 18446344
pmcid: 2516183
Summers P, Saia G, Colombo A, Pricolo P, Zugni F, Alessi S, Marvaso G, Jereczek-Fossa BA, Bellomi M, Petralia G (2021) Whole-body magnetic resonance imaging: technique, guidelines and key applications. Ecancermedicalscience. https://doi.org/10.3332/ecancer.2021.1164
doi: 10.3332/ecancer.2021.1164
pubmed: 33680078
pmcid: 7929776
Morone M, Bali MA, Tunariu N, Messiou C, Blackledge M, Grazioli L, Koh DM (2017) Whole-body MRI: current applications in oncology. AJR Am J Roentgenol 209(6):W336–W349. https://doi.org/10.2214/AJR.17.17984
doi: 10.2214/AJR.17.17984
pubmed: 28981354
Tunariu N, Blackledge M, Messiou C, Petralia G, Padhani A, Curcean S, Curcean A, Koh DM (2020) What’s new for clinical whole-body MRI (WB-MRI) in the 21st century. Br J Radiol 93(1115):20200562. https://doi.org/10.1259/bjr.20200562
doi: 10.1259/bjr.20200562
pubmed: 32822545
pmcid: 8519652
Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20(6):e302–e312. https://doi.org/10.1016/S1470-2045(19)30309-2.Erratum.In:LancetOncol.2019Jul;20(7):e346 . (PMID: 31162104)
doi: 10.1016/S1470-2045(19)30309-2.Erratum.In:LancetOncol.2019Jul;20(7):e346
pubmed: 31162104
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021) EHA Guidelines Committee. ESMO guidelines committee multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):309–322. https://doi.org/10.1016/j.annonc.2020.11.014
doi: 10.1016/j.annonc.2020.11.014
pubmed: 33549387
NICE guideline [NG35] Myeloma: diagnosis and management. Published: 10 February 2016 Last updated: 25 October 2018
Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, Lai M, Pratt G (2017) British society for haematology guidelines. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 178(3):380–393. https://doi.org/10.1111/bjh.14827
doi: 10.1111/bjh.14827
pubmed: 28677897
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S (2020) ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119–1134. https://doi.org/10.1016/j.annonc.2020.06.011
doi: 10.1016/j.annonc.2020.06.011
pubmed: 32593798
Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, Rosenkrantz AB, Verma S, Margolis DJ, Froemming A, Oto A, Purysko A, Milowsky MI, Schlemmer HP, Eiber M, Morris MJ, Choyke PL, Padhani A, Oldan J, Fanti S, Jain S, Pinto PA, Keegan KA, Porter CR, Coleman JA, Bauman GS, Jani AB, Kamradt JM, Sholes W, Vargas HA (2020) Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol 38(17):1963–1996. https://doi.org/10.1200/JCO.19.02757
doi: 10.1200/JCO.19.02757
pubmed: 31940221
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D (2013) German society of dermatology S3-guideline “diagnosis, therapy and follow-up of melanoma” short version. J Dtsch Dermatol Ges 11(6):563–602. https://doi.org/10.1111/ddg.12044
doi: 10.1111/ddg.12044
pubmed: 23721604
Dummer R, Siano M, Hunger RE, Lindenblatt N, Braun R, Michielin O, Mihic-Probst D, von Moos R, Najafi Y, Guckenberger M, Arnold A (2016) The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 146:w14279. https://doi.org/10.4414/smw.2016.14279
doi: 10.4414/smw.2016.14279
pubmed: 26901103
Li B, Li Q, Nie W, Liu S (2014) Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis. Eur J Radiol 83(2):338–344. https://doi.org/10.1016/j.ejrad.2013.11.017
doi: 10.1016/j.ejrad.2013.11.017
pubmed: 24355655
Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D (2017) Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23(11):e38–e45. https://doi.org/10.1158/1078-0432.CCR-17-0408 . (PMID: 28572266)
doi: 10.1158/1078-0432.CCR-17-0408
pubmed: 28572266
Tabori U, Hansford JR, Achatz MI, Kratz CP, Plon SE, Frebourg T, Brugières L (2017) Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23(11):e32–e37. https://doi.org/10.1158/1078-0432.CCR-17-0574 . (PMID: 28572265)
doi: 10.1158/1078-0432.CCR-17-0574
pubmed: 28572265
Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, Nathanson KL, States LJ, Tomlinson GE, Villani A, Voss SD, Schiffman JD, Wasserman JD (2017) Von hippel-lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75. https://doi.org/10.1158/1078-0432.CCR-17-0547 . (PMID: 28620007)
doi: 10.1158/1078-0432.CCR-17-0547
pubmed: 28620007
Blackledge MD, Tunariu N, Zugni F, Holbrey R, Orton MR, Ribeiro A, Hughes JC, Scurr ED, Collins DJ, Leach MO, Koh DM (2020) Noise-corrected, exponentially weighted, diffusion-weighted MRI (niceDWI) improves image signal uniformity in whole-body imaging of metastatic prostate cancer. Front Oncol 8(10):704. https://doi.org/10.3389/fonc.2020.00704
doi: 10.3389/fonc.2020.00704
Busacchio D, Mazzoni D, Mazzocco K, Pricolo P, Summers PE, Petralia G, Pravettoni G (2023) Psychological characteristics and satisfaction for the whole-body MRI in cancer screening. Psychol Health Med 28(2):548–554. https://doi.org/10.1080/13548506.2022.2126989
doi: 10.1080/13548506.2022.2126989
pubmed: 36148490
Madl JE, Sturmbauer SC, Janka R, Bay S, Rohleder N (2022) Preparing patients according to their individual coping style improves patient experience of magnetic resonance imaging. J Behav Med 45(6):841–854. https://doi.org/10.1007/s10865-022-00361-y
doi: 10.1007/s10865-022-00361-y
pubmed: 36074316
pmcid: 9674768
Mazzocco K, Busacchio D, Summers PE, Marzorati C, Pricolo P, Petralia G, Pravettoni G (2023) Is whole-body magnetic resonance imaging a source of anxiety in oncological patients? Cancer Rep (Hoboken) 6(3):e1737. https://doi.org/10.1002/cnr2.1737
doi: 10.1002/cnr2.1737
pubmed: 36494325
Ahlander BM, Årestedt K, Engvall J, Maret E, Ericsson E (2016) Development and validation of a questionnaire evaluating patient anxiety during magnetic resonance imaging: the magnetic resonance imaging-anxiety questionnaire (MRI-AQ). J Adv Nurs 72(6):1368–1380. https://doi.org/10.1111/jan.12917
doi: 10.1111/jan.12917
pubmed: 26893007
Harris LM, Cumming SR, Menzies RG (2004) Predicting anxiety in magnetic resonance imaging scans. Int J Behav Med 11(1):1–7. https://doi.org/10.1207/s15327558ijbm1101_1
doi: 10.1207/s15327558ijbm1101_1
pubmed: 15194514
Eshed I, Althoff CE, Hamm B, Hermann KG (2007) Claustrophobia and premature termination of magnetic resonance imaging examinations. J Magn Reson Imaging 26(2):401–404. https://doi.org/10.1002/jmri.21012
doi: 10.1002/jmri.21012
pubmed: 17610281
Gabr RE, Narayana PA (2016). Patient Distraction and Entertainment System for Magnetic Resonance Imaging using Visual Effects Synchronized to the Scanner Acoustic Noise.
Oztek MA, Brunnquell CL, Hoff MN, Boulter DJ, Mossa-Basha M, Beauchamp LH, Haynor DL, Nguyen XV (2020) Practical considerations for radiologists in implementing a patient-friendly MRI experience. Top Magn Reson Imaging 29(4):181–186. https://doi.org/10.1097/RMR.0000000000000247
doi: 10.1097/RMR.0000000000000247
pubmed: 32511199
Földes Z, Ala-Ruona E, Burger B, Orsi G (2017) Anxiety reduction with music and tempo synchronization on magnetic resonance imaging patients. Psychomusicology Music Mind and Brain 27(4):343–349
doi: 10.1037/pmu0000199
Törnqvist E, Månsson A, Larsson EM, Hallström I (2006) Impact of extended written information on patient anxiety and image motion artifacts during magnetic resonance imaging. Acta Radiol 47(5):474–480. https://doi.org/10.1080/02841850600690355
doi: 10.1080/02841850600690355
pubmed: 16796309
Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Østergaard B, Schlemmer HP, Landgren O, Asmussen JT, Kaiser MF, Padhani A (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 291(1):5–13. https://doi.org/10.1148/radiol.2019181949
doi: 10.1148/radiol.2019181949
pubmed: 30806604
Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1):81–92. https://doi.org/10.1016/j.eururo.2016.05.033
doi: 10.1016/j.eururo.2016.05.033
pubmed: 27317091
pmcid: 5176005
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978–94–92671–19–6. EAU Guidelines Office, Arnhem. https://uroweb.org/guidelines/prostate-cancer
All-in-One Prostate Cancer Staging With MRI (AllinOne MRI). ClinicalTrials.gov ID: NCT06071195.
Morote J, Celma A, Roche S, de Torres IM, Mast R, Semedey ME, Regis L, Planas J (2019) Who benefits from multiparametric magnetic resonance imaging after suspicion of prostate cancer? Eur Urol Oncol 2(6):664–669. https://doi.org/10.1016/j.euo.2018.11.009
doi: 10.1016/j.euo.2018.11.009
pubmed: 31411977
Giannarini G, Petralia G, Thoeny HC (2012) Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 61(2):326–340. https://doi.org/10.1016/j.eururo.2011.09.019
doi: 10.1016/j.eururo.2011.09.019
pubmed: 22000497
Petralia G, Thoeny HC (2010) DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging 10(1A):S112. https://doi.org/10.1102/1470-7330.2010.9030
doi: 10.1102/1470-7330.2010.9030
pubmed: 20880781
pmcid: 2967148
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) European association of Urology EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479. https://doi.org/10.1016/j.eururo.2013.11.002
doi: 10.1016/j.eururo.2013.11.002
pubmed: 24321502
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for Localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177(2):540–545. https://doi.org/10.1016/j.juro.2006.10.097
doi: 10.1016/j.juro.2006.10.097
pubmed: 17222629
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029
doi: 10.1016/j.ijrobp.2006.04.029
pubmed: 16798415
Zugni F, Padhani AR, Koh DM, Summers PE, Bellomi M, Petralia G (2020) Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging 20(1):34. https://doi.org/10.1186/s40644-020-00315-0
doi: 10.1186/s40644-020-00315-0
pubmed: 32393345
pmcid: 7216394
Petralia G, Koh DM, Attariwala R, Busch JJ, Eeles R, Karow D, Lo GG, Messiou C, Sala E, Vargas HA, Zugni F, Padhani AR (2021) Oncologically relevant findings reporting and data system (ONCO-RADS): guidelines for the acquisition, interpretation, and reporting of whole-body MRI for cancer screening. Radiology 299(3):494–507. https://doi.org/10.1148/radiol.2021201740
doi: 10.1148/radiol.2021201740
pubmed: 33904776
Forstner R, Sala E, Kinkel K, Spencer JA (2010) European society of urogenital radiology ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 20(12):2773–2780. https://doi.org/10.1007/s00330-010-1886-4
doi: 10.1007/s00330-010-1886-4
pubmed: 20839002
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N (2021) ESMO guidelines committee electronic address clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475–1495. https://doi.org/10.1016/j.annonc.2021.09.019
doi: 10.1016/j.annonc.2021.09.019
pubmed: 34678411
Kosmin M, Padhani AR, Gogbashian A, Woolf D, Ah-See ML, Ostler P, Sutherland S, Miles D, Noble J, Koh DM, Marshall A, Dunn J, Makris A (2020) Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology 297(3):622–629. https://doi.org/10.1148/radiol.2020192683
doi: 10.1148/radiol.2020192683
pubmed: 33078998
Zugni F, Ruju F, Pricolo P, Alessi S, Iorfida M, Colleoni MA, Bellomi M, Petralia G (2018) The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer. PLoS ONE 3(10):e0205251. https://doi.org/10.1371/journal.pone.0205251
doi: 10.1371/journal.pone.0205251
Fischerova D, Pinto P, Burgetova A, Masek M, Slama J, Kocian R, Frühauf F, Zikan M, Dusek L, Dundr P, Cibula D (2022) Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study). Ultrasound Obstet Gynecol 59(2):248–262. https://doi.org/10.1002/uog.23654
doi: 10.1002/uog.23654
pubmed: 33871110
Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, Leunen K, Berteloot P, Moerman P, Vergote I, Vandecaveye V (2017) Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 83:88–98. https://doi.org/10.1016/j.ejca.2017.06.010
doi: 10.1016/j.ejca.2017.06.010
pubmed: 28734146
Engbersen MP, van Sant IT, Lok C, Lambregts DMJ, Sonke GS, Beets-Tan RGH, van Driel WJ, Lahaye MJ (2019) MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. European J Radiol 114:146–151. https://doi.org/10.1016/j.ejrad.2019.03.007
doi: 10.1016/j.ejrad.2019.03.007
Garcia Prado J, González Hernando C, Varillas Delgado D, Saiz Martínez R, Bhosale P, Blazquez Sanchez J, Chiva L (2019) Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: Diagnostic performance in correlation with surgical findings. Eur J Radiol 121:108696. https://doi.org/10.1016/j.ejrad.2019.108696
doi: 10.1016/j.ejrad.2019.108696
pubmed: 31683251
The impact of multiparametric MRI on the staging and management of patients with suspected or confirmed ovarian cancer.2015 20/11/2018 Available from: http://www.isrctn.com/ISRCTN51246892
Clinical Impact of Dedicated MR Staging of Ovarian Cancer. Available from: https://ClinicalTrials.gov/show/NCT03399344
Müller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, Khorchidi S, Nägele T, Garbe C, Claussen CD, Schlemmer HP (2006) Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 42(3):342–350. https://doi.org/10.1016/j.ejca.2005.10.008
doi: 10.1016/j.ejca.2005.10.008
pubmed: 16364631
Petralia G, Padhani A, Summers P, Alessi S, Raimondi S, Testori A, Bellomi M (2013) Whole-body diffusion-weighted imaging is it all we need for detecting metastases in melanoma patients? Eur Radiol 23(12):3466–3476
doi: 10.1007/s00330-013-2968-x
pubmed: 23884300
Knill AK, Blackledge MD, Curcean A, Larkin J, Turajlic S, Riddell A, Koh DM, Messiou C, Winfield JM (2023) Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma. Eur Radiol 33(2):863–871. https://doi.org/10.1007/s00330-022-09088-5
doi: 10.1007/s00330-022-09088-5
pubmed: 36169688
Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE, Grazioli L, Colagrande S, Giovagnoni A, Bellomi M (2019) Italian working group on magnetic resonance whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiol Med 124(3):218–233. https://doi.org/10.1007/s11547-018-0955-7
doi: 10.1007/s11547-018-0955-7
pubmed: 30430385
Wielpütz MO, Lee HY, Koyama H, Yoshikawa T, Seki S, Kishida Y, Sakai Y, Kauczor HU, Sugimura K, Ohno Y (2018) Morphologic characterization of pulmonary nodules with ultrashort TE MRI at 3T. AJR Am J Roentgenol 210(6):1216–1225. https://doi.org/10.2214/AJR.17.18961
doi: 10.2214/AJR.17.18961
pubmed: 29547055
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M (2023). NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020 .
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E (2023) ESMO guidelines committee. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003
doi: 10.1016/j.annonc.2022.10.003
pubmed: 36307056
Davies J, Chew C, Bromham N, Hoskin P (2022) NICE 2020 guideline for the management of colorectal cancer. Lancet Oncol 23(6):247. https://doi.org/10.1016/S1470-2045(22)00256-X
doi: 10.1016/S1470-2045(22)00256-X
Taylor SA, Mallett S, Beare S, Bhatnagar G, Blunt D, Boavida P, Bridgewater J, Clarke CS, Duggan M, Ellis S, Glynne-Jones R, Goh V, Groves AM, Hameeduddin A, Janes SM, Johnston EW, Koh DM, Miles A, Morris S, Morton A, Navani N, O’Donohue J, Oliver A, Padhani AR, Pardoe H, Patel U, Punwani S, Quinn L, Rafiee H, Reczko K, Rockall AG, Shahabuddin K, Sidhu HS, Teague J, Thaha MA, Train M, van Ree K, Wijeyekoon S, Halligan S (2019) Streamline investigators diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective streamline C trial. Lancet Gastroenterol Hepatol. 4(7):529–537. https://doi.org/10.1016/S2468-1253(19)30056-1
doi: 10.1016/S2468-1253(19)30056-1
pubmed: 31080095
pmcid: 6547166
Engbersen MP, Aalbers AGJ, Van’t Sant-Jansen I, Velsing JDR, Lambregts DMJ, Beets-Tan RGH, Kok NFM, Lahaye MJ (2020) Extent of peritoneal metastases on preoperative DW-MRI is predictive of disease-free and overall survival for CRS/HIPEC candidates with colorectal cancer. Ann Surg Oncol 27(9):3516–3524. https://doi.org/10.1245/s10434-020-08416-7
doi: 10.1245/s10434-020-08416-7
pubmed: 32239338
van Sant I, Nerad E, Rijsemus CJV, Engbersen MP, Gispen CA, Lambregts DMJ, Beets-Tan RGH, Aalbers AGJ, Kok NFM, Lahaye MJ (2022) Seeing the whole picture: added value of MRI for extraperitoneal findings in CRS-HIPEC candidates. European J Surg Oncol 48(2):462–546
doi: 10.1016/j.ejso.2021.09.014
Kwee TC, Vermoolen MA, Akkerman EA, Kersten MJ, Fijnheer R, Ludwig I, Beek FJ, van Leeuwen MS, Bierings MB, Bruin MC, Zsíros J, Quarles van Ufford HM, de Klerk JM, Adam J, Stoker J, Uiterwaal CS, Nievelstein RA (2014) Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J Magn Reson Imaging 40(1):26–36. https://doi.org/10.1002/jmri.24356
doi: 10.1002/jmri.24356
pubmed: 24307538
Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, D’Sa S, Dikaios N, Sokolska M, Antonelli M, Ourselin S, Yong K, Taylor SA, Halligan S, Punwani S (2017) Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol 27(12):5325–5336. https://doi.org/10.1007/s00330-017-4907-8
doi: 10.1007/s00330-017-4907-8
pubmed: 28656463
pmcid: 5674123
Ruhlmann V, Ruhlmann M, Bellendorf A, Grueneisen J, Sawicki LM, Grafe H, Forsting M, Bockisch A, Umutlu L (2016) Hybrid imaging for detection of carcinoma of unknown primary: a preliminary comparison trial of whole-body PET/MRI versus PET/CT. Eur J Radiol 85(11):1941–1947. https://doi.org/10.1016/j.ejrad.2016.08.020
doi: 10.1016/j.ejrad.2016.08.020
pubmed: 27776644
Liang X, Congxin W, Yi Z, Jinwen H, Chuanfu L (2011) Whole-body diffusion-weighted MR imaging with fat suppression by using STIR: clinical utility for detection of primary malignancies in patients initially presented with metastasis. Eur J Radiol 79(3):359–362. https://doi.org/10.1016/j.ejrad.2010.02.013
doi: 10.1016/j.ejrad.2010.02.013
pubmed: 20334989